ScreenerHero

PRTA Prothena Corporation plc

NAS · US · Healthcare · Biotechnology · prothena.com
8.480USD+5.74%Mkt Cap: 435.34M $P/E: —

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap435.34M USD
Enterprise Value130.52M USD
Revenue (TTM)54.53M USD
Gross Profit-10.42M USD
Net Income (TTM)-244.09M USD
Revenue/Share1.02 USD
Last Price8.480 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees67
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.28
PEG—
EV/EBITDA-2.21
EV/Revenue2.39
P/S7.55
P/B1.45
EPS (TTM)-0.82
EPS (Forward)-1.52
52W Range
7.73018% of range11.80
52W High11.80 USD
52W Low7.730 USD
Profitability
Gross Margin-19.11%
Oper. Margin-1850.20%
EBITDA Margin-108.27%
Profit Margin-2520.57%
ROE-87.03%
ROA-74.69%
Growth
Revenue Growth-77.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-163.58M USD
CapEx (TTM)138.00K USD
FCF Margin-99.44%
FCF Yield-12.46%
Net Debt-281.20M USD
Net Debt/EBITDA4.76
Balance Sheet
Debt/Equity0.03
Current Ratio25.05
Quick Ratio24.72
Book Value/Sh5.54 USD
Cash/Share5.61 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)21.40 USD
Upside (mean)+152.4%
Target Range8.000 USD – 36.00 USD
8.000+152.4% to mean36.00
# Analysts5
Ownership
Shares Out.51.34M
Float34.54M
Insiders22.35%
Institutions93.91%
Short Interest
Short Ratio25.4d
Short % Float20.05%
Short % Out.16.64%
Shares Short8.54M
Short (prev mo.)8.55M
Technical
SMA 508.871 (-4.4%)
SMA 2009.314 (-9.0%)
Beta-0.29
S&P 52W Chg15.78%
Avg Vol (30d)463.45K
Avg Vol (10d)528.38K
Technical Indicators
RSI (14)46.5
MACD-0.2028
MACD Signal-0.1601
MACD Hist.-0.0427
BB Upper9.627 USD
BB Middle8.710 USD
BB Lower7.794 USD
BB Width21.05%
ATR (14)0.4355 USD
Vol Ratio (20d)1.35x